Ribavirin News and Research

RSS
Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.
Inhibitex commences trials on INX-189 for treatment of Hepatitis C infections

Inhibitex commences trials on INX-189 for treatment of Hepatitis C infections

Pharmasset reports net loss of $16.1 million for fiscal second-quarter 2010

Pharmasset reports net loss of $16.1 million for fiscal second-quarter 2010

Results from STEALTH C-3 clinical trial of nitazoxanide presented at DDW 2010

Results from STEALTH C-3 clinical trial of nitazoxanide presented at DDW 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Clinical development of RG7128 is on track: Pharmasset

Clinical development of RG7128 is on track: Pharmasset

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Valeant Pharmaceuticals International reports 30% increase in total revenue for first-quarter 2010

Valeant Pharmaceuticals International reports 30% increase in total revenue for first-quarter 2010

Extended hepatitis C treatment increases sustained virological response after liver transplant

Extended hepatitis C treatment increases sustained virological response after liver transplant

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Human Genome Sciences reports net loss of $47.9M for first-quarter 2010

Human Genome Sciences reports net loss of $47.9M for first-quarter 2010

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

ChronSeal multi-center study in Sweden and Norway finalized

ChronSeal multi-center study in Sweden and Norway finalized

UK MHRA authorizes Presidio Pharmaceuticals to initiate Phase 1 clinical trial of PPI-461 for HCV

UK MHRA authorizes Presidio Pharmaceuticals to initiate Phase 1 clinical trial of PPI-461 for HCV

Phase II study: Hepatitis C patients receiving ANA598 bid plus SOC attain undetectable levels of virus

Phase II study: Hepatitis C patients receiving ANA598 bid plus SOC attain undetectable levels of virus

G1 HCV patients having fast antiviral response to TVR with PEG-IFN and RBV can be cured in 24 weeks

G1 HCV patients having fast antiviral response to TVR with PEG-IFN and RBV can be cured in 24 weeks

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Positive interim data from Idera Pharmaceuticals' Phase 1 trial of IMO-2125 TLR9 agonist presented at 45th EASL

Positive interim data from Idera Pharmaceuticals' Phase 1 trial of IMO-2125 TLR9 agonist presented at 45th EASL

Results from Romark Laboratories' STEALTH C-3 clinical trial presented at EASL Annual Meeting

Results from Romark Laboratories' STEALTH C-3 clinical trial presented at EASL Annual Meeting

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

Smith & Nephew to launch new line extensions to ACTICOAT antimicrobial barrier dressing portfolio

Smith & Nephew to launch new line extensions to ACTICOAT antimicrobial barrier dressing portfolio

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.